Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. QCOM
5. IONS
6. AZN
7. ROIV
8. AAPL
9. HOOD
10. QQQ

Go back to Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
(NASDAQ: NTLA) Delayed: 12.74 --0 (-0%)
Previous Close $12.74    52 Week High $30.40 
Open $12.83    52 Week Low $11.86 
Day High $12.89    P/E N/A 
Day Low $12.43    EPS $0.00 
Volume 4,129,194